Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

被引：0

作者：

Ogdie, Alexis ^{[1
]}

Mease, Philip ^{[2
,3
]}

Nantel, Francois ^{[4
]}

Lavie, Frederic ^{[5
]}

Sharaf, Mohamed ^{[6
]}

Rampakakis, Emmanouil ^{[7
]}

Marzo-Ortega, Helena ^{[8
,9
]}

Gossec, Laure ^{[10
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA

[2] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[3] Univ Washington, Sch Med, Seattle, WA USA

[4] Nantel MedSci Consult, Montreal, PQ, Canada

[5] Janssen Cilag Global Med Affairs, Immunol Global Med Affairs, Issy Les Moulineaux, France

[6] Middle East FZ LLC, Johnson & Johnson, Dubai, U Arab Emirates

[7] McGill Univ, Dept Pediat Sci Affairs, JSS Med Res Inc, Montreal, PQ, Canada

[8] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England

[9] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[10] Sorbonne Univ, Paris, France

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

IMPORTANT-DIFFERENCE;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0583

引用

页码：1184 / 1187

页数：4

共 50 条

[31] Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
Georg Schett
Warner Chen
Sheng Gao
Soumya D. Chakravarty
May Shawi
Frederic Lavie
Miriam Zimmermann
Mohamed Sharaf
Laura C. Coates
Stefan Siebert
Arthritis Research & Therapy, 25
[32] EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
Coates, L. C.
Gossec, L.
Theander, E.
Bergmans, P.
Neuhold, M.
Karyekar, C.
Shawi, M.
Noel, W.
Schett, G.
Mcinnes, I.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 140 - 141
[33] Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Eder, Lihi
Gladman, Dafna
Aydin, Sibel Zehra
Ogdie, Alexis
Shi, Harry
Landry, Pierre-Alexandre
Luna, Rayana
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[34] Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Eder, Lihi
Gladman, Dafna
Aydin, Sibel
Ogdie, Alexis
Shi, Harry
Landry, Pierre-Alexandre
Luna, Rayana
JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1043 - 1044
[35] Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Eder, Lihi
Selmi, Carlo
Mease, Philip
Ogdie, Alexis
Nantel, Francois
Lavie, Frederic
Sharaf, Mohamed
Adelakun, Oyediran
Rampakakis, Emmanouil
Vegas, Laura Pina
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4720 - 4722
[36] Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
Soriano, Enrique
Kishimoto, Mitsumasa
Rampakakis, Emmanouil
Nantel, Francois
Shawi, May
Lavie, Frederic
Mease, Philip J.
Gladman, Dafna
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2834 - 2837
[37] Effects of guselkumab on musculoskeletal features in patients with active psoriatic arthritis by baseline skin disease: Results from the phase 3 DISCOVER-1 and DISCOVER-2 studies
Gottlieb, Alice B.
Mease, Philip
Rahman, Proton
Kollmeier, Alexa P.
Zhou, Bei
McInnes, Iain B.
Deodhar, Atul
Helliwell, Philip
Ritchlin, Christopher T.
Boehncke, Wolf-Henning
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36
[38] Ixekizumab reduces disease activity up to 52 weeks in active psoriatic arthritis patients with inadequate response to tumor necrosis factor inhibitors: An assessment with the use of minimal disease activity scores
Merola, Joseph F.
Coates, Laura C.
Husni, M. Elaine
Adams, David H.
Rathmann, Suchitrita S.
Helliwell, Philip
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB174 - AB174
[39] Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
Tillett, William
Rednic, Simona
Mizelle, Kristi
Ritchlin, Christopher
Khattri, Saakshi
Shi, Linyu
Bialik, Brenton
Iyile, Thomas
Kavanaugh, Arthur
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2981 - 2983
[40] Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
Ogdie, Alexis
Merola, Joseph F.
Mease, Philip J.
Ritchlin, Christopher T.
Scher, Jose U.
Lafferty, Kimberly Parnell
Chan, Daphne
Chakravarty, Soumya D.
Langholff, Wayne
Wang, Yanli
Choi, Olivia
Krol, Yevgeniy
Gottlieb, Alice B.
BMC RHEUMATOLOGY, 2024, 8 (01)

← 1 2 3 4 5 →